GSK Investigational Site

Jasper, Alabama 35501

0 studies enrolling now · 36 studies all time

What they study most

Asthma, Cough, Infections, Bacterial, Lung Cancer, Non-Small Cell, Migraine Disorders, Neuropathy, Diabetic, Pulmonary Disease, Chronic Obstructive, Refractory Chronic Cough, Restless Legs Syndrome, Restless Legs Syndrome (RLS)

Studies at this site

• A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough — Completed
• Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level — Completed
• Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Compared With Vilanterol (VI) Inhalation Powder on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD). — Completed
• A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD) — Completed
• Validation of a New Shortness of Breath With Daily Activities Questionnaire in Patients With Chronic Obstructive Pulmonary Disease — Completed
• A Study to Evaluate the Effect of the Combination of Umeclidinium (UMEC) and Vilanterol (VI) on Exercise Endurance Time (EET) in Participants With Chronic Obstructive Pulmonary Disease (COPD) — Completed
• An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B — Completed
• Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD) — Completed
• Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks — Completed
• A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD — Completed
• Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD) — Completed
• Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) — Completed
• Ease of Use and Correct Use Study of Placebo ELLIPTA® Inhaler in COPD Subjects — Completed
• A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) — Completed
• A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD) — Completed
• Observational Study Of An Electronic Questionnaire In Patients With Chronic Obstructive Pulmonary Disease (COPD) — Completed
• Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD) — Completed
• 24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease — Completed
• A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer — Stopped early
• A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2) — Completed
• A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD) — Completed
• Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD) — Completed
• Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations — Completed
• A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD) — Completed
• Advair HFA For Chronic Obstructive Pulmonary Disease(COPD) — Completed
• Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease) — Completed
• Long-Term Safety Of Ropinirole XR In Patients With Restless Legs Syndrome — Completed
• 12-week Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome — Completed
• ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the GSK Group of Companies. — Completed
• A Clinical Research Study Testing Ropinirole Treatment for Restless Legs Syndrome — Completed
• Ropinirole XR (Extended Release) In Patients With Restless Legs Syndrome — Completed
• A Clinical Research Study Evaluating Ropinirole Treatment For Restless Legs Syndrome (RLS) — Completed
• GSK BHR Study (Sont - Second Study) — Completed
• DISKUS vs. ELLIPTA Device Preference Study in Chronic Obstructive Pulmonary Disease (COPD) — Completed
• Polysomnography Study of GSK1838262 Extended Release Tablets Versus Placebo in RLS and Associated Sleep Disturbance — Completed
• A Study In Patients With Neuropathic Pain From Diabetic Peripheral Neuropathy (DPN) — Completed